Drugs / Mononuclear cells
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07698080 | Jul 2026 → Jul 2028 expected | aplastic anemia, leukemia, lymphoma, myelodysplastic syndrome +1 | Hematology department of the 920th hospital | Not yet recruiting | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT05808010 | Jun 2023 → Apr 2025 | chronic atrophic gastritis | Shandong Provincial Hospital | Unknown | No outcome recorded |
| — | NCT06427642 | Apr 2022 → May 2024 | brain hypoxia - ischemia, bronchopulmonary dysplasia, short bowel syndrome | Shandong Qilu Stem Cells Engineering Co., Ltd. | Unknown | No outcome recorded |
| — | NCT04893629 | May 2021 → Nov 2024 | cardiomyopathy | Damascus University | Terminated | No outcome recorded |
| — | NCT02721940 | Feb 2012 → Jan 2015 | osteonecrosis | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01456819 Comparator | Mar 2011 → Dec 2015 | limb ischemia | National University of Malaysia | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mononuclear cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05808010 ↗ |
| Modality | Cell therapy | “Cell therapy with mononuclear cells and mesenchymal stem cells from bone marrow is promising” NCT01456819 ↗ |
| Route | Other | “purified bone marrow mononuclear cells will be injected into the necrotic zone” NCT02721940 ↗ |